Oncology Nurse Educator - San Francisco / Los Angeles

Replimune is pioneering a novel class of oncolytic immunotherapies specifically designed to target and kill tumors locally, alter the tumor microenvironment, and ignite a robust patient-specific immune response. The development of these transformational therapies is aimed at addressing the challenges posed by difficult-to-treat cancers. By focusing on both recognizing the tumor as a foreign entity and overcoming the immune response that tumors often shut down, Replimune is at the forefront of a new approach in cancer treatment.

Through ongoing clinical trials, Replimune is evaluating the safety and effectiveness of its investigational therapies across a range of solid tumor cancers. These therapies are assessed both as stand-alone treatments and in combination with other existing immunotherapies, showcasing the company’s innovative strategy to enhance patient outcomes. The commitment to advancing these therapies exemplifies Replimune's dedication to improving the lives of those affected by challenging cancer types.